Shares of HAOHAI BIOTEC (06826.HK), a leading Chinese biotechnology company, plummeted over 12% on Friday following the release of the firm's disappointing third-quarter earnings results.
According to its latest filing with the Hong Kong Stock Exchange, HAOHAI BIOTEC reported a net profit attributable to shareholders of 105.6 million yuan ($15.9 million) for the quarter ended September 30th, 2024. This represented a staggering 13.13% decline compared to the same period last year. Earnings per share also dropped by 11.76% year-over-year to 0.45 yuan.
While the company's revenue increased marginally by 0.22% to 670.4 million yuan ($100.8 million), HAOHAI BIOTEC's weaker profitability clearly overshadowed the modest top-line growth. This significant miss against market expectations caused widespread concerns among investors, prompting a massive sell-off that saw the firm's shares plunge 12.24% to close at HK$30.25 on the day.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。